ArticleJournal of managed care & specialty pharmacy2023

Adverse event costs associated with first-line therapy for advanced non-small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors.

David Stenehjem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.